TapewireFind a company

person · Reporting owner

POON CHRISTINE A

Disclosed activity across 6 companies

Tapewire entity
13319
SEC CIK
0001189014

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Decibel Therapeutics, Inc.DBTX · Entity 109458DirectorFebruary 11, 2021February 16, 2021
JOHNSON & JOHNSONJNJ · Entity 2722Director · Vice ChairmanFebruary 12, 2009February 18, 2009
NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655DirectorMay 27, 2026May 29, 2026
PRUDENTIAL FINANCIAL INCPRU · Entity 148DirectorSeptember 10, 2026September 14, 2026
REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010DirectorJanuary 02, 2026January 06, 2026
SHERWIN WILLIAMS COSHW · Entity 2948DirectorApril 04, 2025April 07, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Decibel Therapeutics, Inc.

Report date February 11, 2021 · Filed February 16, 2021

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2031-02-10Direct20,000 Reported balance After 2021-02-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2021-02-11 · Grant · Acquired 20,000 · Balance 20,000

F1: The option was granted on February 11, 2021 for 20,000 shares. The shares underlying the option vest in equal monthly installments until the third anniversary of the grant date, subject to the reporting person's continued service.

Filing footnotes · ownership attribution and instrument terms

F1: The option was granted on February 11, 2021 for 20,000 shares. The shares underlying the option vest in equal monthly installments until the third anniversary of the grant date, subject to the reporting person's continued service.

JOHNSON & JOHNSON

Report date February 12, 2009 · Filed February 18, 2009

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
CommonSEC Table I · non-derivativeDirect55,711 Ending reported balance After 2009-02-13 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2009-02-13 · Exercise / conversion · Acquired 17,141 · Balance 61,942

Row 2 · 2009-02-13 · Tax withholding · Disposed 6,231 · Balance 55,711

Phantom Stock UnitsSEC Table II · derivative / convertible securityDirect16,165 Reported balance After 2009-02-12 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2009-02-12 · Grant · Acquired 3,949 · Balance 16,165

F3: The Phantom Stock converts into Common Stock on a one-for-one basis.

F4: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on February 12, 2009 at $56.97 per share are to be settled in cash upon the Reporting Person's Retirement.

Restricted Share UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2009-02-13 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2009-02-13 · Exercise / conversion · Disposed 17,141 · Balance 0

F5: Each Restricted Share Unit, awarded under Issuer's Long-Term Incentive Plan on February 13, 2006, represents a contingent right to receive one share of Company Common Stock.

F6: Not applicable.

CommonSEC Table I · non-derivativeIndirectJohnson & Johnson Stock Fund under the 401(k) Savings Plan16 Reported balance Holding disclosure · report date 2009-02-12 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 16

F1: Shares held in the Johnson & Johnson Stock Fund under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (01/30/2009).

CommonSEC Table I · non-derivativeIndirectESOP under the 401(k) Savings Plan162 Reported balance Holding disclosure · report date 2009-02-12 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 162

F2: Shares held by ESOP under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (01/30/2009).

Filing footnotes · ownership attribution and instrument terms

F1: Shares held in the Johnson & Johnson Stock Fund under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (01/30/2009).

F2: Shares held by ESOP under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (01/30/2009).

F3: The Phantom Stock converts into Common Stock on a one-for-one basis.

F4: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on February 12, 2009 at $56.97 per share are to be settled in cash upon the Reporting Person's Retirement.

F5: Each Restricted Share Unit, awarded under Issuer's Long-Term Incentive Plan on February 13, 2006, represents a contingent right to receive one share of Company Common Stock.

F6: Not applicable.

NEUROCRINE BIOSCIENCES INC

Report date May 27, 2026 · Filed May 29, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Restriced Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct2,567 Reported balance After 2026-05-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-05-27 · Grant · Acquired 2,567 · Balance 2,567

F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

F2: The RSUs will vest in full on May 27, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

F2: The RSUs will vest in full on May 27, 2027.

PRUDENTIAL FINANCIAL INC

Report date September 10, 2026 · Filed September 14, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Notional Shares - MandatorySEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct13,840 Reported balance After 2026-09-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-09-10 · Grant · Acquired 161 · Balance 13,840

F1: Each notional share - mandatory represents a deferred stock unit and entitles the holder thereof with the right to receive one share of Issuer common stock under the Issuer's deferred compensation plan for non-employee directors.

F2: Such shares are issuable, at the election of the reporting person, to begin on either (i) a date prior to the reporting person's retirement date, provided that such date is no earlier than the January 1 in the year following the plan period during which such fees would otherwise have been payable to the reporting person, (ii) within 90 days following the reporting person's retirement date, or (iii) such later date as selected by the reporting person, provided however, that payment must commence in the year the reporting person attains age 70 1/2.

Notional Shares - OptionalSEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct4,248 Reported balance After 2026-09-10 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-09-10 · Grant · Acquired 49 · Balance 4,248

F3: Each notional share - optional represents a deferred stock unit and entitles the holder thereof with the right to receive one share of Issuer common stock or the cash value thereof under the Issuer's deferred compensation plan for non-employee directors.

F4: Such shares are payable in common stock or cash, at the election of the reporting person, with payment to begin, at the election of the reporting person provided that such date shall be at least two (2) years after the end of the plan year with respect to which such elective deferrals relate. The reporting person may transfer her investment in the notional shares - optional to an alternative investment account, subject to the terms of the Issuer's deferred compensation plan for non-employee directors.

2026 Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct1,798 Reported balance After 2026-09-10 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-09-10 · Grant · Acquired 21 · Balance 1,798

F5: Each restricted stock unit represents a contingent right to receive the economic equivalent of one share of PRU common stock.

F6: The restricted stock units vest the earlier of the annual meeting or in one year on May 12, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: Each notional share - mandatory represents a deferred stock unit and entitles the holder thereof with the right to receive one share of Issuer common stock under the Issuer's deferred compensation plan for non-employee directors.

F2: Such shares are issuable, at the election of the reporting person, to begin on either (i) a date prior to the reporting person's retirement date, provided that such date is no earlier than the January 1 in the year following the plan period during which such fees would otherwise have been payable to the reporting person, (ii) within 90 days following the reporting person's retirement date, or (iii) such later date as selected by the reporting person, provided however, that payment must commence in the year the reporting person attains age 70 1/2.

F3: Each notional share - optional represents a deferred stock unit and entitles the holder thereof with the right to receive one share of Issuer common stock or the cash value thereof under the Issuer's deferred compensation plan for non-employee directors.

F4: Such shares are payable in common stock or cash, at the election of the reporting person, with payment to begin, at the election of the reporting person provided that such date shall be at least two (2) years after the end of the plan year with respect to which such elective deferrals relate. The reporting person may transfer her investment in the notional shares - optional to an alternative investment account, subject to the terms of the Issuer's deferred compensation plan for non-employee directors.

F5: Each restricted stock unit represents a contingent right to receive the economic equivalent of one share of PRU common stock.

F6: The restricted stock units vest the earlier of the annual meeting or in one year on May 12, 2027.

REGENERON PHARMACEUTICALS, INC.

Report date January 02, 2026 · Filed January 06, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect5,219 Reported balance After 2026-01-02 transaction · row 1
1 source row

Row 1 · 2026-01-02 · Grant · Acquired 155 · Balance 5,219

F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.

Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $772.76 · Expires 2036-01-02Direct1,962 Reported balance After 2026-01-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-01-02 · Grant · Acquired 1,962 · Balance 1,962

F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.

F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.

SHERWIN WILLIAMS CO

Report date April 04, 2025 · Filed April 07, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectDeferred Fee Plan2,573.38 Reported balance After 2025-04-04 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 1 · 2025-04-04 · Grant · Acquired 4.11 · Balance 2,573.38

F1: Represents the number of deferred stock units acquired by the Reporting Person, in an exempt transaction, pursuant to the 2005 Director Deferred Fee Plan ("Deferred Fee Plan"). Each deferred stock unit is the economic equivalent of one share of common stock. The deferred stock units become payable solely in stock, generally following the Reporting Person's separation from service as a Director of the Company.

F2: Represents the weighted average share price on the transaction date used to determine the number of deferred stock units credited to the Reporting Person's account.

F3: These securities consist of deferred stock units, held pursuant to the Deferred Fee Plan, and include deferred stock units acquired pursuant to the dividend reinvestment feature of such Plan.

Common StockSEC Table I · non-derivativeDirect12,386 Reported balance Holding disclosure · report date 2025-04-04 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 12,386

F4: These securities consist of 1,150 restricted stock units ("RSUs") and 11,236 shares of common stock. Each RSU represents the Reporting Person's right to receive one share of common stock.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the number of deferred stock units acquired by the Reporting Person, in an exempt transaction, pursuant to the 2005 Director Deferred Fee Plan ("Deferred Fee Plan"). Each deferred stock unit is the economic equivalent of one share of common stock. The deferred stock units become payable solely in stock, generally following the Reporting Person's separation from service as a Director of the Company.

F2: Represents the weighted average share price on the transaction date used to determine the number of deferred stock units credited to the Reporting Person's account.

F3: These securities consist of deferred stock units, held pursuant to the Deferred Fee Plan, and include deferred stock units acquired pursuant to the dividend reinvestment feature of such Plan.

F4: These securities consist of 1,150 restricted stock units ("RSUs") and 11,236 shares of common stock. Each RSU represents the Reporting Person's right to receive one share of common stock.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
January 02, 2025 Filed Jan 6, 2025 21:07 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 GrantNon-Qualified Stock Option (right to buy) · Derivative 1,958 $0.00 Strike: $719.37 $0.00
Disclosure

SEC source: 0001968202-25-000006 · edgardoc.xml · derivative · entry 3

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,958

Underlying: Common Stock · 1,958 shares

Expires 2035-01-02

F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.

Read SEC document
January 02, 2025 Filed Jan 6, 2025 21:07 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 GrantCommon Stock 166 $0.00 $0.00
Disclosure

SEC source: 0001968202-25-000006 · edgardoc.xml · nonDerivative · entry 2

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,352

F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.

Read SEC document
December 20, 2024 Filed Jan 6, 2025 21:07 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 OtherCommon Stock 14 $0.00 $0.00
Disclosure

SEC source: 0001968202-25-000006 · edgardoc.xml · nonDerivative · entry 1

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,186

Read SEC document
December 12, 2024 Filed Dec 16, 2024 22:08 UTC PRUDENTIAL FINANCIAL INC PRU · Entity 148 Grant2024 Restricted Stock Units · Derivative 13 $120.61 Strike: $0.00 $1,567.93
Disclosure

SEC source: 0001127602-24-029508 · form4.xml · derivative · entry 3

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,304

Underlying: Common Stock · 13 shares

Expires not disclosed

F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of PRU common stock.

F6 · derivative.exercise_date: The restricted stock units vest the earlier of the annual meeting or in one year on May 14, 2025.

F6 · derivative.expiration_date: The restricted stock units vest the earlier of the annual meeting or in one year on May 14, 2025.

Read SEC document
December 12, 2024 Filed Dec 16, 2024 22:08 UTC PRUDENTIAL FINANCIAL INC PRU · Entity 148 GrantNotional Shares - Optional · Derivative 41 $120.61 Strike: $0.00 $4,945.01
Disclosure

SEC source: 0001127602-24-029508 · form4.xml · derivative · entry 2

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,884

Underlying: Common Stock · 41 shares

Expires not disclosed

F3 · derivative.exercise_price: Each notional share - optional represents a deferred stock unit and entitles the holder thereof with the right to receive one share of Issuer common stock or the cash value thereof under the Issuer's deferred compensation plan for non-employee directors.

F4 · derivative.exercise_date: Such shares are payable in common stock or cash, at the election of the reporting person, with payment to begin, at the election of the reporting person provided that such date shall be at least two (2) years after the end of the plan year with respect to which such elective deferrals relate. The reporting person may transfer her investment in the notional shares - optional to an alternative investment account, subject to the terms of the Issuer's deferred compensation plan for non-employee directors.

F4 · derivative.expiration_date: Such shares are payable in common stock or cash, at the election of the reporting person, with payment to begin, at the election of the reporting person provided that such date shall be at least two (2) years after the end of the plan year with respect to which such elective deferrals relate. The reporting person may transfer her investment in the notional shares - optional to an alternative investment account, subject to the terms of the Issuer's deferred compensation plan for non-employee directors.

Read SEC document
December 12, 2024 Filed Dec 16, 2024 22:08 UTC PRUDENTIAL FINANCIAL INC PRU · Entity 148 GrantNotional Shares - Mandatory · Derivative 134 $120.61 Strike: $0.00 $16,161.74
Disclosure

SEC source: 0001127602-24-029508 · form4.xml · derivative · entry 1

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,656

Underlying: Common Stock · 134 shares

Expires not disclosed

F1 · derivative.exercise_price: Each notional share - mandatory represents a deferred stock unit and entitles the holder thereof with the right to receive one share of Issuer common stock under the Issuer's deferred compensation plan for non-employee directors.

F2 · derivative.exercise_date: Such shares are issuable, at the election of the reporting person, to begin on either (i) a date prior to the reporting person's retirement date, provided that such date is no earlier than the January 1 in the year following the plan period during which such fees would otherwise have been payable to the reporting person, (ii) within 90 days following the reporting person's retirement date, or (iii) such later date as selected by the reporting person, provided however, that payment must commence in the year the reporting person attains age 70 1/2.

F2 · derivative.expiration_date: Such shares are issuable, at the election of the reporting person, to begin on either (i) a date prior to the reporting person's retirement date, provided that such date is no earlier than the January 1 in the year following the plan period during which such fees would otherwise have been payable to the reporting person, (ii) within 90 days following the reporting person's retirement date, or (iii) such later date as selected by the reporting person, provided however, that payment must commence in the year the reporting person attains age 70 1/2.

Read SEC document
October 04, 2024 Filed Oct 8, 2024 21:58 UTC SHERWIN WILLIAMS CO SHW · Entity 2948 GrantCommon Stock 22.65 $372.47 $8,436.45
Disclosure

SEC source: 0000089800-24-000125 · wk-form4_1728424724.xml · nonDerivative · entry 1

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Deferred Fee Plan

Disclosed balance after: 2,533.5

F1 · shares: Represents the number of deferred stock units acquired by the Reporting Person, in an exempt transaction, pursuant to the 2005 Director Deferred Fee Plan ("Deferred Fee Plan"). Each deferred stock unit is the economic equivalent of one share of common stock. The deferred stock units become payable solely in stock, generally following the Reporting Person's separation from service as a Director of the Company.

F2 · price: Represents the weighted average share price on the transaction date used to determine the number of deferred stock units to be credited to the Reporting Person's account.

F3 · balance_after: These securities consist of deferred stock units, held pursuant to the Deferred Fee Plan, and include deferred stock units acquired pursuant to the dividend reinvestment feature of such Plan.

Read SEC document
September 12, 2024 Filed Sep 16, 2024 21:31 UTC PRUDENTIAL FINANCIAL INC PRU · Entity 148 Grant2024 Restricted Stock Units · Derivative 14 $115.84 Strike: $0.00 $1,621.76
Disclosure

SEC source: 0001127602-24-024019 · form4.xml · derivative · entry 3

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,290

Underlying: Common Stock · 14 shares

Expires not disclosed

F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of PRU common stock.

F6 · derivative.exercise_date: The restricted stock units vest the earlier of the annual meeting or in one year on May 14, 2025.

F6 · derivative.expiration_date: The restricted stock units vest the earlier of the annual meeting or in one year on May 14, 2025.

Read SEC document
September 12, 2024 Filed Sep 16, 2024 21:31 UTC PRUDENTIAL FINANCIAL INC PRU · Entity 148 GrantNotional Shares - Optional · Derivative 42 $115.84 Strike: $0.00 $4,865.28
Disclosure

SEC source: 0001127602-24-024019 · form4.xml · derivative · entry 2

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,843

Underlying: Common Stock · 42 shares

Expires not disclosed

F3 · derivative.exercise_price: Each notional share - optional represents a deferred stock unit and entitles the holder thereof with the right to receive one share of Issuer common stock or the cash value thereof under the Issuer's deferred compensation plan for non-employee directors.

F4 · derivative.exercise_date: Such shares are payable in common stock or cash, at the election of the reporting person, with payment to begin, at the election of the reporting person provided that such date shall be at least two (2) years after the end of the plan year with respect to which such elective deferrals relate. The reporting person may transfer her investment in the notional shares - optional to an alternative investment account, subject to the terms of the Issuer's deferred compensation plan for non-employee directors.

F4 · derivative.expiration_date: Such shares are payable in common stock or cash, at the election of the reporting person, with payment to begin, at the election of the reporting person provided that such date shall be at least two (2) years after the end of the plan year with respect to which such elective deferrals relate. The reporting person may transfer her investment in the notional shares - optional to an alternative investment account, subject to the terms of the Issuer's deferred compensation plan for non-employee directors.

Read SEC document
September 12, 2024 Filed Sep 16, 2024 21:31 UTC PRUDENTIAL FINANCIAL INC PRU · Entity 148 GrantNotional Shares - Mandatory · Derivative 138 $115.84 Strike: $0.00 $15,985.92
Disclosure

SEC source: 0001127602-24-024019 · form4.xml · derivative · entry 1

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,521

Underlying: Common Stock · 138 shares

Expires not disclosed

F1 · derivative.exercise_price: Each notional share - mandatory represents a deferred stock unit and entitles the holder thereof with the right to receive one share of Issuer common stock under the Issuer's deferred compensation plan for non-employee directors.

F2 · derivative.exercise_date: Such shares are issuable, at the election of the reporting person, to begin on either (i) a date prior to the reporting person's retirement date, provided that such date is no earlier than the January 1 in the year following the plan period during which such fees would otherwise have been payable to the reporting person, (ii) within 90 days following the reporting person's retirement date, or (iii) such later date as selected by the reporting person, provided however, that payment must commence in the year the reporting person attains age 70 1/2.

F2 · derivative.expiration_date: Such shares are issuable, at the election of the reporting person, to begin on either (i) a date prior to the reporting person's retirement date, provided that such date is no earlier than the January 1 in the year following the plan period during which such fees would otherwise have been payable to the reporting person, (ii) within 90 days following the reporting person's retirement date, or (iii) such later date as selected by the reporting person, provided however, that payment must commence in the year the reporting person attains age 70 1/2.

Read SEC document
August 15, 2024 Filed Aug 19, 2024 20:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 10,838 $0.00 Strike: $413.33 $0.00
Disclosure

SEC source: 0001968202-24-000122 · edgardoc.xml · derivative · entry 9

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,838 shares

Expires 2025-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.

Read SEC document
August 15, 2024 Filed Aug 19, 2024 20:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 100 $1,161.32 $116,132.00
Disclosure

SEC source: 0001968202-24-000122 · edgardoc.xml · nonDerivative · entry 8

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,172

Read SEC document
August 15, 2024 Filed Aug 19, 2024 20:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 234 $1,160.45 $271,545.30
Disclosure

SEC source: 0001968202-24-000122 · edgardoc.xml · nonDerivative · entry 7

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,272

F6 · price: Represents volume-weighted average price of sales of 234 shares of Company stock on August 15, 2024 at prices ranging from $1,160.10 to $1,160.72. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 15, 2024 at each separate price.

Read SEC document
August 15, 2024 Filed Aug 19, 2024 20:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 5,352 $1,159.56 $6,205,965.12
Disclosure

SEC source: 0001968202-24-000122 · edgardoc.xml · nonDerivative · entry 6

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,506

F5 · price: Represents volume-weighted average price of sales of 5,352 shares of Company stock on August 15, 2024 at prices ranging from $1,159.18 to $1,159.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 15, 2024 at each separate price.

Read SEC document
August 15, 2024 Filed Aug 19, 2024 20:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 212 $1,158.02 $245,500.24
Disclosure

SEC source: 0001968202-24-000122 · edgardoc.xml · nonDerivative · entry 5

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,858

F4 · price: Represents volume-weighted average price of sales of 212 shares of Company stock on August 15, 2024 at prices ranging from $1,158.01 to $1,158.08. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 15, 2024 at each separate price.

Read SEC document
August 15, 2024 Filed Aug 19, 2024 20:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 1,560 $1,157.33 $1,805,434.80
Disclosure

SEC source: 0001968202-24-000122 · edgardoc.xml · nonDerivative · entry 4

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,070

F3 · price: Represents volume-weighted average price of sales of 1,560 shares of Company stock on August 15, 2024 at prices ranging from $1,157.02 to $1,157.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 15, 2024 at each separate price.

Read SEC document
August 15, 2024 Filed Aug 19, 2024 20:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 2,368 $1,156.30 $2,738,118.40
Disclosure

SEC source: 0001968202-24-000122 · edgardoc.xml · nonDerivative · entry 3

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,630

F2 · price: Represents volume-weighted average price of sales of 2,368 shares of Company stock on August 15, 2024 at prices ranging from $1,156.04 to $1,156.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 15, 2024 at each separate price.

Read SEC document
August 15, 2024 Filed Aug 19, 2024 20:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 1,012 $1,155.72 $1,169,588.64
Disclosure

SEC source: 0001968202-24-000122 · edgardoc.xml · nonDerivative · entry 2

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,998

F1 · price: Represents volume-weighted average price of sales of 1,012 shares of Company stock on August 15, 2024 at prices ranging from $1,155.38 to $1,155.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 15, 2024 at each separate price.

Read SEC document
August 15, 2024 Filed Aug 19, 2024 20:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Exercise / conversionCommon Stock 10,838 $413.33 $4,479,670.54
Disclosure

SEC source: 0001968202-24-000122 · edgardoc.xml · nonDerivative · entry 1

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,010

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 05, 2024 Filed Jul 9, 2024 21:11 UTC SHERWIN WILLIAMS CO SHW · Entity 2948 GrantCommon Stock 28.55 $295.50 $8,436.53
Disclosure

SEC source: 0000089800-24-000098 · wk-form4_1720559484.xml · nonDerivative · entry 1

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Deferred Fee Plan

Disclosed balance after: 2,505.9

F1 · shares: Represents the number of deferred stock units acquired by the Reporting Person, in an exempt transaction, pursuant to the 2005 Director Deferred Fee Plan ("Deferred Fee Plan"). Each deferred stock unit is the economic equivalent of one share of common stock. The deferred stock units become payable solely in stock, generally following the Reporting Person's separation from service as a Director of the Company.

F2 · price: Represents the weighted average share price on the transaction date used to determine the number of deferred stock units to be credited to the Reporting Person's account.

F3 · balance_after: These securities consist of deferred stock units, held pursuant to the Deferred Fee Plan, and include deferred stock units acquired pursuant to the dividend reinvestment feature of such Plan.

Read SEC document
June 13, 2024 Filed Jun 17, 2024 22:54 UTC PRUDENTIAL FINANCIAL INC PRU · Entity 148 Grant2024 Restricted Stock Units · Derivative 14 $113.97 Strike: $0.00 $1,595.58
Disclosure

SEC source: 0001127602-24-018867 · form4.xml · derivative · entry 3

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,276

Underlying: Common Stock · 14 shares

Expires not disclosed

F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive the economic equivalent of one share of PRU common stock.

F6 · derivative.exercise_date: The restricted stock units vest the earlier of the annual meeting or in one year on May 14, 2025.

F6 · derivative.expiration_date: The restricted stock units vest the earlier of the annual meeting or in one year on May 14, 2025.

Read SEC document
June 13, 2024 Filed Jun 17, 2024 22:54 UTC PRUDENTIAL FINANCIAL INC PRU · Entity 148 GrantNotional Shares - Optional · Derivative 42 $113.97 Strike: $0.00 $4,786.74
Disclosure

SEC source: 0001127602-24-018867 · form4.xml · derivative · entry 2

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,800

Underlying: Common Stock · 42 shares

Expires not disclosed

F3 · derivative.exercise_price: Each notional share - optional represents a deferred stock unit and entitles the holder thereof with the right to receive one share of Issuer common stock or the cash value thereof under the Issuer's deferred compensation plan for non-employee directors.

F4 · derivative.exercise_date: Such shares are payable in common stock or cash, at the election of the reporting person, with payment to begin, at the election of the reporting person provided that such date shall be at least two (2) years after the end of the plan year with respect to which such elective deferrals relate. The reporting person may transfer her investment in the notional shares - optional to an alternative investment account, subject to the terms of the Issuer's deferred compensation plan for non-employee directors.

F4 · derivative.expiration_date: Such shares are payable in common stock or cash, at the election of the reporting person, with payment to begin, at the election of the reporting person provided that such date shall be at least two (2) years after the end of the plan year with respect to which such elective deferrals relate. The reporting person may transfer her investment in the notional shares - optional to an alternative investment account, subject to the terms of the Issuer's deferred compensation plan for non-employee directors.

Read SEC document
June 13, 2024 Filed Jun 17, 2024 22:54 UTC PRUDENTIAL FINANCIAL INC PRU · Entity 148 GrantNotional Shares - Mandatory · Derivative 139 $113.97 Strike: $0.00 $15,841.83
Disclosure

SEC source: 0001127602-24-018867 · form4.xml · derivative · entry 1

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,382

Underlying: Common Stock · 139 shares

Expires not disclosed

F1 · derivative.exercise_price: Each notional share - mandatory represents a deferred stock unit and entitles the holder thereof with the right to receive one share of Issuer common stock under the Issuer's deferred compensation plan for non-employee directors.

F2 · derivative.exercise_date: Such shares are issuable, at the election of the reporting person, to begin on either (i) a date prior to the reporting person's retirement date, provided that such date is no earlier than the January 1 in the year following the plan period during which such fees would otherwise have been payable to the reporting person, (ii) within 90 days following the reporting person's retirement date, or (iii) such later date as selected by the reporting person, provided however, that payment must commence in the year the reporting person attains age 70 1/2.

F2 · derivative.expiration_date: Such shares are issuable, at the election of the reporting person, to begin on either (i) a date prior to the reporting person's retirement date, provided that such date is no earlier than the January 1 in the year following the plan period during which such fees would otherwise have been payable to the reporting person, (ii) within 90 days following the reporting person's retirement date, or (iii) such later date as selected by the reporting person, provided however, that payment must commence in the year the reporting person attains age 70 1/2.

Read SEC document
May 22, 2024 Filed May 23, 2024 22:45 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 GrantNon-Qualified Stock Option · Derivative 2,982 $0.00 Strike: $139.43 $0.00
Disclosure

SEC source: 0000914475-24-000156 · wk-form4_1716504314.xml · derivative · entry 2

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,982

Underlying: Common Stock · 2,982 shares

Expires 2034-05-22

F3 · derivative.exercise_date: Option vests in 12 monthly installments beginning June 22, 2024.

Read SEC document
May 22, 2024 Filed May 23, 2024 22:45 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 GrantRestricted Stock Unit · Derivative 1,435 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000914475-24-000156 · wk-form4_1716504314.xml · derivative · entry 1

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,435

Underlying: Common Stock · 1,435 shares

Expires not disclosed

F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: The RSUs will vest in full on May 22, 2025.

F2 · derivative.expiration_date: The RSUs will vest in full on May 22, 2025.

Read SEC document
May 14, 2024 Filed May 16, 2024 19:36 UTC PRUDENTIAL FINANCIAL INC PRU · Entity 148 Grant2024 Restricted Stock Units · Derivative 1,261 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001127602-24-015596 · form4.xml · derivative · entry 1

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,261

Underlying: Common Stock · 1,261 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive the economic equivalent of one share of PRU common stock.

F2 · derivative.exercise_date: The restricted stock units vest the earlier of the annual meeting or in one year on May 14, 2025.

F2 · derivative.expiration_date: The restricted stock units vest the earlier of the annual meeting or in one year on May 14, 2025.

Read SEC document
May 09, 2024 Filed May 13, 2024 20:38 UTC PRUDENTIAL FINANCIAL INC PRU · Entity 148 Exercise / conversion2023 Restricted Stock Units · Derivative 1,935 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001127602-24-015103 · form4.xml · derivative · entry 3

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,935 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive the economic equivalent of one share of PRU common stock.

F2 · derivative.exercise_date: The restricted stock units vest the earlier of the annual meeting or in one year on May 9, 2024.

F2 · derivative.expiration_date: The restricted stock units vest the earlier of the annual meeting or in one year on May 9, 2024.

Read SEC document
May 09, 2024 Filed May 13, 2024 20:38 UTC PRUDENTIAL FINANCIAL INC PRU · Entity 148 Disposition to issuerCommon Stock 1,935 $117.95 $228,233.25
Disclosure

SEC source: 0001127602-24-015103 · form4.xml · nonDerivative · entry 2

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,583

Read SEC document
May 09, 2024 Filed May 13, 2024 20:38 UTC PRUDENTIAL FINANCIAL INC PRU · Entity 148 Exercise / conversionCommon Stock 1,935 $0.00 $0.00
Disclosure

SEC source: 0001127602-24-015103 · form4.xml · nonDerivative · entry 1

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,518

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 05, 2024 Filed Apr 9, 2024 20:56 UTC SHERWIN WILLIAMS CO SHW · Entity 2948 GrantCommon Stock 25.45 $331.56 $8,438.20
Disclosure

SEC source: 0000089800-24-000077 · wk-form4_1712696162.xml · nonDerivative · entry 1

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Deferred Fee Plan

Disclosed balance after: 2,471.34

F1 · shares: Represents the number of deferred stock units acquired by the Reporting Person, in an exempt transaction, pursuant to the 2005 Director Deferred Fee Plan ("Deferred Fee Plan"). Each deferred stock unit is the economic equivalent of one share of common stock. The deferred stock units become payable solely in stock, generally following the Reporting Person's separation from service as a Director of the Company.

F2 · price: Represents the weighted average share price on the transaction date used to determine the number of deferred stock units to be credited to the Reporting Person's account.

F3 · balance_after: These securities consist of deferred stock units, held pursuant to the Deferred Fee Plan, and include deferred stock units acquired pursuant to the dividend reinvestment feature of such Plan.

Read SEC document
March 14, 2024 Filed Mar 18, 2024 21:15 UTC PRUDENTIAL FINANCIAL INC PRU · Entity 148 Grant2023 Restricted Stock Units · Derivative 22 $111.74 Strike: $0.00 $2,458.28
Disclosure

SEC source: 0001127602-24-010467 · form4.xml · derivative · entry 3

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,935

Underlying: Common Stock · 22 shares

Expires not disclosed

F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive the economic equivalent of one share of PRU common stock.

F6 · derivative.exercise_date: The restricted stock units vest the earlier of the annual meeting or in one year on May 9, 2024.

F6 · derivative.expiration_date: The restricted stock units vest the earlier of the annual meeting or in one year on May 9, 2024.

Read SEC document
March 14, 2024 Filed Mar 18, 2024 21:15 UTC PRUDENTIAL FINANCIAL INC PRU · Entity 148 GrantNotional Shares - Optional · Derivative 43 $111.74 Strike: $0.00 $4,804.82
Disclosure

SEC source: 0001127602-24-010467 · form4.xml · derivative · entry 2

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,757

Underlying: Common Stock · 43 shares

Expires not disclosed

F3 · derivative.exercise_price: Each notional share - optional represents a deferred stock unit and entitles the holder thereof with the right to receive one share of Issuer common stock or the cash value thereof under the Issuer's deferred compensation plan for non-employee directors.

F4 · derivative.exercise_date: Such shares are payable in common stock or cash, at the election of the reporting person, with payment to begin, at the election of the reporting person provided that such date shall be at least two (2) years after the end of the plan year with respect to which such elective deferrals relate. The reporting person may transfer her investment in the notional shares - optional to an alternative investment account, subject to the terms of the Issuer's deferred compensation plan for non-employee directors.

F4 · derivative.expiration_date: Such shares are payable in common stock or cash, at the election of the reporting person, with payment to begin, at the election of the reporting person provided that such date shall be at least two (2) years after the end of the plan year with respect to which such elective deferrals relate. The reporting person may transfer her investment in the notional shares - optional to an alternative investment account, subject to the terms of the Issuer's deferred compensation plan for non-employee directors.

Read SEC document
March 14, 2024 Filed Mar 18, 2024 21:15 UTC PRUDENTIAL FINANCIAL INC PRU · Entity 148 GrantNotional Shares - Mandatory · Derivative 140 $111.74 Strike: $0.00 $15,643.60
Disclosure

SEC source: 0001127602-24-010467 · form4.xml · derivative · entry 1

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,243

Underlying: Common Stock · 140 shares

Expires not disclosed

F1 · derivative.exercise_price: Each notional share - mandatory represents a deferred stock unit and entitles the holder thereof with the right to receive one share of Issuer common stock under the Issuer's deferred compensation plan for non-employee directors.

F2 · derivative.exercise_date: Such shares are issuable, at the election of the reporting person, to begin on either (i) a date prior to the reporting person's retirement date, provided that such date is no earlier than the January 1 in the year following the plan period during which such fees would otherwise have been payable to the reporting person, (ii) within 90 days following the reporting person's retirement date, or (iii) such later date as selected by the reporting person, provided however, that payment must commence in the year the reporting person attains age 70 1/2.

F2 · derivative.expiration_date: Such shares are issuable, at the election of the reporting person, to begin on either (i) a date prior to the reporting person's retirement date, provided that such date is no earlier than the January 1 in the year following the plan period during which such fees would otherwise have been payable to the reporting person, (ii) within 90 days following the reporting person's retirement date, or (iii) such later date as selected by the reporting person, provided however, that payment must commence in the year the reporting person attains age 70 1/2.

Read SEC document
February 13, 2024 Filed Feb 16, 2024 00:21 UTC SHERWIN WILLIAMS CO SHW · Entity 2948 GrantCommon Stock 594 $0.00 $0.00
Disclosure

SEC source: 0000089800-24-000019 · wk-form4_1708042877.xml · nonDerivative · entry 1

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,869

F1 · kind: Grant of restricted stock units ("RSUs") under The Sherwin-Williams Company 2006 Stock Plan for Nonemployee Directors.

F2 · balance_after: These securities consist of 1,244 RSUs and 10,625 shares of common stock. Each RSU represents the Reporting Person's right to receive one share of common stock.

Read SEC document
January 05, 2024 Filed Jan 9, 2024 21:56 UTC SHERWIN WILLIAMS CO SHW · Entity 2948 GrantCommon Stock 28.41 $296.96 $8,436.63
Disclosure

SEC source: 0000089800-24-000004 · wk-form4_1704837377.xml · nonDerivative · entry 1

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Deferred Fee Plan

Disclosed balance after: 2,440.83

F1 · kind: Represents the number of deferred stock units acquired by the Reporting Person, in an exempt transaction, pursuant to the 2005 Director Deferred Fee Plan ("Deferred Fee Plan"). Each deferred stock unit is the economic equivalent of one share of common stock. The deferred stock units become payable solely in stock, generally following the Reporting Person's separation from service as a Director of the Company.

F2 · price: Represents the weighted average share price on the transaction date used to determine the number of deferred stock units to be credited to the Reporting Person's account.

F3 · balance_after: These securities consist of deferred stock units, held pursuant to the Deferred Fee Plan, and include deferred stock units acquired pursuant to the dividend reinvestment feature of such Plan.

Read SEC document
January 02, 2024 Filed Jan 4, 2024 21:10 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 GrantNon-Qualified Stock Option (right to buy) · Derivative 1,607 $0.00 Strike: $888.34 $0.00
Disclosure

SEC source: 0001968202-24-000026 · edgardoc.xml · derivative · entry 2

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,607

Underlying: Common Stock · 1,607 shares

Expires 2034-01-02

F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.

Read SEC document
January 02, 2024 Filed Jan 4, 2024 21:10 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 GrantCommon Stock 135 $0.00 $0.00
Disclosure

SEC source: 0001968202-24-000026 · edgardoc.xml · nonDerivative · entry 1

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,172

F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.

Read SEC document
December 14, 2023 Filed Dec 18, 2023 16:56 UTC PRUDENTIAL FINANCIAL INC PRU · Entity 148 Grant2023 Restricted Stock Units · Derivative 22 $105.21 Strike: $0.00 $2,314.62
Disclosure

SEC source: 0001127602-23-029774 · form4.xml · derivative · entry 3

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,913

Underlying: Common Stock · 22 shares

Expires not disclosed

F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of PRU common stock.

F6 · derivative.exercise_date: The restricted stock units vest the earlier of the annual meeting or in one year on May 9, 2024.

F6 · derivative.expiration_date: The restricted stock units vest the earlier of the annual meeting or in one year on May 9, 2024.

Read SEC document
December 14, 2023 Filed Dec 18, 2023 16:56 UTC PRUDENTIAL FINANCIAL INC PRU · Entity 148 GrantNotional Shares - Optional · Derivative 43 $105.21 Strike: $0.00 $4,524.03
Disclosure

SEC source: 0001127602-23-029774 · form4.xml · derivative · entry 2

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,714

Underlying: Common Stock · 43 shares

Expires not disclosed

F3 · derivative.exercise_price: Each notional share - optional represents a deferred stock unit and entitles the holder thereof with the right to receive one share of Issuer common stock or the cash value thereof under the Issuer's deferred compensation plan for non-employee directors.

F4 · derivative.exercise_date: Such shares are payable in common stock or cash, at the election of the reporting person, with payment to begin, at the election of the reporting person provided that such date shall be at least two (2) years after the end of the plan year with respect to which such elective deferrals relate. The reporting person may transfer her investment in the notional shares - optional to an alternative investment account, subject to the terms of the Issuer's deferred compensation plan for non-employee directors.

F4 · derivative.expiration_date: Such shares are payable in common stock or cash, at the election of the reporting person, with payment to begin, at the election of the reporting person provided that such date shall be at least two (2) years after the end of the plan year with respect to which such elective deferrals relate. The reporting person may transfer her investment in the notional shares - optional to an alternative investment account, subject to the terms of the Issuer's deferred compensation plan for non-employee directors.

Read SEC document
December 14, 2023 Filed Dec 18, 2023 16:56 UTC PRUDENTIAL FINANCIAL INC PRU · Entity 148 GrantNotional Shares - Mandatory · Derivative 142 $105.21 Strike: $0.00 $14,939.82
Disclosure

SEC source: 0001127602-23-029774 · form4.xml · derivative · entry 1

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,102

Underlying: Common Stock · 142 shares

Expires not disclosed

F1 · derivative.exercise_price: Each notional share - mandatory represents a deferred stock unit and entitles the holder thereof with the right to receive one share of Issuer common stock under the Issuer's deferred compensation plan for non-employee directors.

F2 · derivative.exercise_date: Such shares are issuable, at the election of the reporting person, to begin on either (i) a date prior to the reporting person's retirement date, provided that such date is no earlier than the January 1 in the year following the plan period during which such fees would otherwise have been payable to the reporting person, (ii) within 90 days following the reporting person's retirement date, or (iii) such later date as selected by the reporting person, provided however, that payment must commence in the year the reporting person attains age 70 1/2.

F2 · derivative.expiration_date: Such shares are issuable, at the election of the reporting person, to begin on either (i) a date prior to the reporting person's retirement date, provided that such date is no earlier than the January 1 in the year following the plan period during which such fees would otherwise have been payable to the reporting person, (ii) within 90 days following the reporting person's retirement date, or (iii) such later date as selected by the reporting person, provided however, that payment must commence in the year the reporting person attains age 70 1/2.

Read SEC document
October 06, 2023 Filed Oct 10, 2023 12:48 UTC SHERWIN WILLIAMS CO SHW · Entity 2948 GrantCommon Stock 32.1 $253.15 $8,126.12
Disclosure

SEC source: 0001209191-23-052407 · doc4.xml · nonDerivative · entry 1

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Deferred Plan

Disclosed balance after: 2,407.42

F1 · kind: Represents the number of phantom stock units acquired by the reporting person (in an exempt transaction) under the 2005 Director Deferred Fee Plan. Each phantom stock unit is the economic equivalent of one share of common stock. The phantom stock units become payable solely in stock generally upon the reporting person's retirement.

F2 · balance_after: Phantom stock units listed are held pursuant to the 2005 Director Deferred Fee Plan, which includes phantom stock units acquired pursuant to the dividend reinvestment feature of such plan.

Read SEC document
September 14, 2023 Filed Sep 18, 2023 19:47 UTC PRUDENTIAL FINANCIAL INC PRU · Entity 148 Grant2023 Restricted Stock Units · Derivative 23 $99.14 Strike: $0.00 $2,280.22
Disclosure

SEC source: 0001127602-23-024292 · form4.xml · derivative · entry 3

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,890

Underlying: Common Stock · 23 shares

Expires not disclosed

F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of PRU common stock.

F6 · derivative.exercise_date: The restricted stock units vest the earlier of the annual meeting or in one year on May 9, 2024.

F6 · derivative.expiration_date: The restricted stock units vest the earlier of the annual meeting or in one year on May 9, 2024.

Read SEC document
September 14, 2023 Filed Sep 18, 2023 19:47 UTC PRUDENTIAL FINANCIAL INC PRU · Entity 148 GrantNotional Shares - Optional · Derivative 45 $99.14 Strike: $0.00 $4,461.30
Disclosure

SEC source: 0001127602-23-024292 · form4.xml · derivative · entry 2

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,671

Underlying: Common Stock · 45 shares

Expires not disclosed

F3 · derivative.exercise_price: Each notional share - optional represents a deferred stock unit and entitles the holder thereof with the right to receive one share of Issuer common stock or the cash value thereof under the Issuer's deferred compensation plan for non-employee directors.

F4 · derivative.exercise_date: Such shares are payable in common stock or cash, at the election of the reporting person, with payment to begin, at the election of the reporting person provided that such date shall be at least two (2) years after the end of the plan year with respect to which such elective deferrals relate. The reporting person may transfer her investment in the notional shares - optional to an alternative investment account, subject to the terms of the Issuer's deferred compensation plan for non-employee directors.

F4 · derivative.expiration_date: Such shares are payable in common stock or cash, at the election of the reporting person, with payment to begin, at the election of the reporting person provided that such date shall be at least two (2) years after the end of the plan year with respect to which such elective deferrals relate. The reporting person may transfer her investment in the notional shares - optional to an alternative investment account, subject to the terms of the Issuer's deferred compensation plan for non-employee directors.

Read SEC document
September 14, 2023 Filed Sep 18, 2023 19:47 UTC PRUDENTIAL FINANCIAL INC PRU · Entity 148 GrantNotional Shares - Mandatory · Derivative 148 $99.14 Strike: $0.00 $14,672.72
Disclosure

SEC source: 0001127602-23-024292 · form4.xml · derivative · entry 1

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,960

Underlying: Common Stock · 148 shares

Expires not disclosed

F1 · derivative.exercise_price: Each notional share - mandatory represents a deferred stock unit and entitles the holder thereof with the right to receive one share of Issuer common stock under the Issuer's deferred compensation plan for non-employee directors.

F2 · derivative.exercise_date: Such shares are issuable, at the election of the reporting person, to begin on either (i) a date prior to the reporting person's retirement date, provided that such date is no earlier than the January 1 in the year following the plan period during which such fees would otherwise have been payable to the reporting person, (ii) within 90 days following the reporting person's retirement date, or (iii) such later date as selected by the reporting person, provided however, that payment must commence in the year the reporting person attains age 70 1/2.

F2 · derivative.expiration_date: Such shares are issuable, at the election of the reporting person, to begin on either (i) a date prior to the reporting person's retirement date, provided that such date is no earlier than the January 1 in the year following the plan period during which such fees would otherwise have been payable to the reporting person, (ii) within 90 days following the reporting person's retirement date, or (iii) such later date as selected by the reporting person, provided however, that payment must commence in the year the reporting person attains age 70 1/2.

Read SEC document
August 23, 2023 Filed Aug 25, 2023 20:02 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 12,280 $0.00 Strike: $273.67 $0.00
Disclosure

SEC source: 0001968202-23-000029 · edgardoc.xml · derivative · entry 7

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,280 shares

Expires 2024-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.

Read SEC document
August 23, 2023 Filed Aug 25, 2023 20:02 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 500 $841.05 $420,525.00
Disclosure

SEC source: 0001968202-23-000029 · edgardoc.xml · nonDerivative · entry 6

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,037

F5 · price: Represents volume-weighted average price of sales of 500 shares of Company stock on August 23, 2023 at prices ranging from $841.02 to $841.16. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2023 at each separate price.

Read SEC document
August 23, 2023 Filed Aug 25, 2023 20:02 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 6,450 $840.65 $5,422,192.50
Disclosure

SEC source: 0001968202-23-000029 · edgardoc.xml · nonDerivative · entry 5

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,537

F4 · price: Represents volume-weighted average price of sales of 6,450 shares of Company stock on August 23, 2023 at prices ranging from $840.01 to $840.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2023 at each separate price.

Read SEC document
August 23, 2023 Filed Aug 25, 2023 20:02 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 3,032 $839.45 $2,545,212.40
Disclosure

SEC source: 0001968202-23-000029 · edgardoc.xml · nonDerivative · entry 4

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,987

F3 · price: Represents volume-weighted average price of sales of 3,032 shares of Company stock on August 23, 2023 at prices ranging from $839.01 to $839.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2023 at each separate price.

Read SEC document
August 23, 2023 Filed Aug 25, 2023 20:02 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 1,998 $838.60 $1,675,522.80
Disclosure

SEC source: 0001968202-23-000029 · edgardoc.xml · nonDerivative · entry 3

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,019

F2 · price: Represents volume-weighted average price of sales 1,998 shares of Company stock on August 23, 2023 at prices ranging from $838.02 to $838.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2023 at each separate price.

Read SEC document
August 23, 2023 Filed Aug 25, 2023 20:02 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 300 $837.92 $251,376.00
Disclosure

SEC source: 0001968202-23-000029 · edgardoc.xml · nonDerivative · entry 2

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,017

F1 · price: Represents volume-weighted average price of sales of 300 shares of Company stock on August 23, 2023 at prices ranging from $837.83 to $837.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2023 at each separate price.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.